Apperley E, Feniuk W, Humphrey P P, Levy G P
Br J Pharmacol. 1980 Feb;68(2):215-24. doi: 10.1111/j.1476-5381.1980.tb10410.x.
1 As part of an investigation into the mode of action of anti-migraine drugs, a study of the excitatory receptors for 5-hydroxytryptamine (5-HT) has been carried out in a range of isolated vascular preparations from the dog.2 5-HT contracted the dog isolated femoral artery and saphenous vein over the concentration-range 1.0 x 10(-8) to 5.0 x 10(-6) mol/l.3 In the femoral artery methysergide and cyproheptadine were potent, competitive and specific antagonists of the contractile responses to 5-HT, with pA(2) values of 8.52 and 8.55 respectively.4 In the saphenous vein, methysergide was only a weak antagonist of 5-HT. In addition, it was an agonist over the concentration-range 5.0 x 10(-8) to 1.0 x 10(-5) mol/l. Cyproheptadine was a weak and unsurmountable antagonist of contractile responses to 5-HT and methysergide.5 Contractile responses to 5-HT and methysergide in the saphenous vein were not antagonized by morphine (3.0 x 10(-5) mol/l), indomethacin (5.0 x 10(-5) mol/l), phentolamine (5.0 x 10(-7) mol/l), propranolol (1.0 x 10(-6) mol/l), atropine (1.0 x 10(-6) mol/l), mepyramine (1.0 x 10(-6) mol/l) or cimetidine (1.0 x 10(-5) mol/l).6 In the external carotid and lingual arteries the pattern of activity obtained with methysergide and cyproheptadine was the same as that in the femoral artery, while in the auricular artery the pattern of activity was the same as that in the saphenous vein.7 The results are consistent with the hypothesis that there are two types of receptor mediating 5-HT-induced vasoconstriction in dog vasculature. One type, characterized by the pattern of activity obtained in the femoral artery, is like the previously described ;D-receptor'. The other type, characterized by the pattern of activity obtained in the saphenous vein, has not been described before. The verification of this hypothesis requires the identification of a specific antagonist of 5-HT and methysergide in the saphenous vein.
作为抗偏头痛药物作用方式研究的一部分,已在一系列犬类离体血管制剂中对5-羟色胺(5-HT)的兴奋性受体进行了研究。
5-HT在1.0×10⁻⁸至5.0×10⁻⁶mol/L的浓度范围内使犬离体股动脉和隐静脉收缩。
在股动脉中,麦角新碱和赛庚啶是对5-HT收缩反应的强效、竞争性和特异性拮抗剂,pA₂值分别为8.52和8.55。
在隐静脉中,麦角新碱只是5-HT的弱拮抗剂。此外,它在5.0×10⁻⁸至1.0×10⁻⁵mol/L的浓度范围内是激动剂。赛庚啶是对5-HT和麦角新碱收缩反应的弱且不可克服的拮抗剂。
隐静脉中对5-HT和麦角新碱的收缩反应不受吗啡(3.0×10⁻⁵mol/L)、吲哚美辛(5.0×10⁻⁵mol/L)、酚妥拉明(5.0×10⁻⁷mol/L)、普萘洛尔(1.0×10⁻⁶mol/L)、阿托品(1.0×10⁻⁶mol/L)、美吡拉敏(1.0×10⁻⁶mol/L)或西咪替丁(1.0×10⁻⁵mol/L)的拮抗。
在外颈动脉和舌动脉中,麦角新碱和赛庚啶产生的活性模式与股动脉中的相同,而在耳动脉中,活性模式与隐静脉中的相同。
这些结果与以下假设一致:在犬类血管系统中存在两种介导5-HT诱导的血管收缩的受体类型。一种类型,以在股动脉中获得的活性模式为特征,类似于先前描述的“D-受体”。另一种类型,以在隐静脉中获得的活性模式为特征,以前尚未描述过。该假设的验证需要鉴定隐静脉中5-HT和麦角新碱的特异性拮抗剂。